Top movers analysis one hour before the close of the markets on 2025-11-11: top gainers and losers in today's session. Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Let's take a look at the stocks that are in motion in today's session. Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Federal Judge Clears Path For GTCR's Takeover Of Surmodics After FTC Challenge A U.S. court denied the FTC's bid to block GTCR's $627 million acquisition of Surmodics, clearing the way for the merger to proceed.
Let's uncover which stocks are experiencing notable gaps during today's session. The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Get insights into the top gainers and losers of Tuesday's pre-market session. Wondering what's happening in Tuesday's pre-market session? Find an overview in this article.
Surmodics Inc (NASDAQ:SRDX) Beats Q3 Earnings Estimates Despite Revenue Challenges, Raises Full-Year Guidance Surmodics Inc (SRDX) beats Q3 earnings estimates with $0.06 EPS, raises FY2025 guidance. Revenue dips 3% but Pounce Thrombectomy grows 35%. Shares rise on improved profitability.
Deal Dispatch: Clock Ticks On TikTok, Raizen Explores Asset Sale, Investors Urge Walgreens To Go Private This week's Deal Dispatch has updates on Raizen, Walgreens, TikTok and Canoo. Plus: the FTC is blocking mergers like it's 2017 again.
Why Surmodics Stock Is Falling On Friday Surmodics stock drops 4.76% in premarket trading following news that the FTC will challenge its proposed acquisition by GTCR.
SRDX Stock Earnings: Surmodics Beats EPS, Beats Revenue for Q3 2024 SRDX stock results show that Surmodics beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2024.
Surmodics Stock Rockets, But Merck Stock Little Moved, On Takeover Deals Surmodics stock hit a two-year high on its GPCR takeover, but Merck stock was little moved on its EyeBio deal.
